Why the study?
Does the addition of spironolactone to an ACE inhibitor or AngII receptor blocker improve proteinuria, blood pressure, and renal function in patients with type 2 diabetic nephropathy?
Does the addition of spironolactone to an ACE inhibitor or AngII receptor blocker improve proteinuria, blood pressure, and renal function in patients with type 2 diabetic nephropathy?
Adding spironolactone to ACEi/ARB therapy in type 2 diabetic nephropathy provides a marked antiproteinuric effect, though this is partly related to a reduction in GFR.
Supports spironolactone addition to ACEi/ARB for proteinuria in diabetic nephropathy; extends dual RAAS blockade evidence with GFR monitoring.
Addition of spironolactone to an ACE inhibitor or AngII receptor blocker is associated with a marked and sustained antiproteinuric effect, which in part relates to the more pronounced reduction in GFR.
No takes yet. Share an insight, caveat, or question.
Meiracker et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: